Key Takeaways
- Revenue down 4.7% on sweetener weakness: Artificial sweetener de-growth drove the decline as management refused to chase cheaper import pricing, sacrificing volume to protect gross margin.
- Contrast media and pharma intermediates delivered: Contrast media grew on both quantity and better price realization, while a newly commercialized cardiac drug created a quantum jump in pharma intermediates revenue.
- A fatal fire at Mahad Unit 3 adds uncertainty: The November 3 incident halted a production block permanently, though ongoing capex at the site is unaffected and the company has adequate insurance.
- Capacity expansion stays on track: The company is adding 50% more capacity to reach 1,500 KL in 18 months, with new launches in contrast media expected in Q4 to Q1 FY25.
- What to watch next quarter: Whether the artificial sweetener business catches up in Q4 as promised, the timeline for reconstructing the fire-affected block, and the pace of new product commercialization in contrast media.
Artificial Sweetener: The Quarter's Drag
- Imported pricing undercut the business: Cheaper imported material took the spot market opportunity in Q2, and management explicitly chose not to drop prices or compromise gross margin to compete.
- Seasonality amplified the pain: Most order cycles for artificial sweetener fall between January and September, so Q2 already carries a seasonal impact that made the pricing-driven volume loss more visible.
- Recovery bet rests on Q4: Management expects to catch up in Q4, implying the order cycle window reopens and pricing dynamics may shift, though no commitment was made on volume or revenue recovery.
Ganesh Karuppannan: "The imported material pricing is cheaper. We are not interested in dropping the prices. We don't want to compromise on the gross margin at this stage."
Contrast Media: The Growth Engine
- H1 growth came from both volume and price: Contrast media grew in the first half by quantity and better price realization, with both contributing to higher turnover.
- New gadolinium intermediates commercialized: The company recently commercialized advanced intermediates for gadolinium-based MRI contrast agents, expanding its molecule set in the space.
- Validation milestone cleared with a top-four player: Plant validation batches for one advanced intermediate were completed with one of the big four contrast media manufacturers, a critical step toward commercialization.
- Step-up growth is event-driven, not linear: CDMO contracts provide moderate growth on existing volumes, but new product and customer launches create step-up growth, and a few launches are planned for Q4 to Q1 FY25.
- The industry's barriers protect incumbents: Contrast media intermediates operate under strict regulatory control where even intermediate-stage product validation takes years, and innovators guard specifications tightly.
Shiven Arora: "Injectables, as you are aware, have a very strict regulatory control. So even at the intermediate stage, product validation takes years."
Pharma Intermediates: Cardiac Drug Ramps Up
- Cardiac esperon drug entered commercialization: The opportunity moved into commercial phase last quarter, producing a quantum jump in pharma intermediate segment revenues and very good traction versus the same period last year.
- Steady monthly offtake expected: As the product stabilizes, management foresees a slight increase in monthly offtake and a steady month-on-month revenue stream.
- New capacity will be ready in time: Additional capacity at Unit II for this drug is expected on stream by the time volumes ramp up, with no delays foreseen from current indications.
- Four or five more opportunities in the pipeline: A couple have already kicked in and entered commercial phase, with ramp-up and strong traction expected in this third vertical.
Fire Incident at Mahad: Operational and Financial Impact
- A production block at Unit 3 is permanently offline: The November 3 fire broke out in a production block, causing casualties and injuries, and that block must be reconstructed with no manufacturing activities going forward.
- Ongoing capex at the site is unaffected: The capex underway at Mahad, including a backward-integration project for an imported raw material, was not impacted by the fire.
- Insurance coverage is adequate: The affected block carries adequate insurance, and the company is cooperating with authorities on the investigation.
- De-risking alternatives are being evaluated: Management is in the process of de-risking operations through other alternatives and will present the plan in a subsequent quarter, though no timeline was given for reconstruction.
Shiven Arora: "It is indeed a heart-wrenching that... we are fully cooperating with the concerned authorities related to the investigations associated with this fire and have put in a mechanism so that we can avoid such incidents to the extent possible."
Capacity, Capex, and the Pipeline
- Capacity quadrupled in four years, with 50% more coming: The company has grown from 230 KL to over 1,000 KL, and will add another 500 KL to reach 1,500 KL in the next 18 months.
- Incremental capacity may earn significantly more per kg: Management cautioned that per-kg realization from incremental capacity could be materially higher than current levels, making simple volume extrapolations misleading.
- Three capex streams are running in parallel: Unit II Ambernath is adding a block, Mahad is adding two new blocks, and Unit IV greenfield awaits environment clearance with capex slated for FY26.
- Mahad's backward-integration project de-risks supply: The capex at Mahad is for making an imported raw material in-house, which de-risks raw material sources but will not contribute to the top line.
- R&D infrastructure has doubled: A new R&D center is constructed, hardware has doubled, and competent scientists have been added to support the 19 products currently in development, sampling, validation, and commercialization stages.
- Solar investment is complete: The company has finished its solar investment and expects to integrate with the grid shortly.
Margins and Cost Structure
- Gross margin above 60% was a COVID outlier: The high-margin period reflected a temporary crash in imported chemical prices during COVID and should not be treated as a sustainable baseline.
- Sustainable gross margin on the existing portfolio is 57-58%: Management believes the company can reach this level but perhaps not beyond it on a sustainable basis.
- Incremental business will land above 50-55% gross margin: New business is assessed to deliver gross margins in excess of 50% to 55%.
- Employee costs will stay in a tight band: Employee cost is expected to remain around 6-7% of revenue, with a marginal increase of a percent or so possible, since senior management is already in place and new hires will be at the operator level for capacity additions.
Ganesh Karuppannan: "If you look at the high margin period, I think that was because of the COVID impact. I think when COVID started, most of the chemical prices crashed. Especially some of the key raw materials we were importing, the prices literally crashed. So, you have to take it as one outlier."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Artificial sweetener recovery | Catch up from Q2 shortfall | Q4 FY24 |
| Contrast media growth | Positive growth for the full financial year based on pipeline | FY24 |
| New contrast media launches | A few launches planned | Q4 FY24 to Q1 FY25 |
| Capacity expansion | Add 50% to reach 1,500 KL | Next 18 months |
| Gross margin on existing portfolio | Reach 57-58% on a sustainable basis | Not specified |
| Gross margin on incremental business | In excess of 50% to 55% | Not specified |
| Employee cost range | Around 6-7%, not beyond 7-8% | Ongoing |
| FY24 capex | Another INR 200 crores | FY24 |
| FY25 capex | Another INR 150 crores for Unit IV greenfield | FY25 |
| Cardiac esperon capacity | New capacity at Unit II on stream by the time volumes ramp up | Aligned with customer ramp |
| New contrast media validation commercialization | Start commercializing | FY24 |
| Fire de-risking plan | Present alternatives to de-risk operations | Subsequent quarter |
Key Metrics
| Metric | Q2 FY24 |
|---|---|
| Revenue | Down 4.7% YoY, owing to de-growth in artificial sweetener |
| EBITDA | ₹62.6 cr, up 6.7% YoY vs ₹58.7 cr in Q2 FY23 |
| EBITDA margin | 34.5%, vs 30.9% in Q2 FY23 |
| PAT | ₹47.9 cr, up 8.9% YoY vs Q2 FY23 |
| PAT margin | 26.4%, vs 23.1% in Q2 FY23 |
| H1 FY24 revenue growth | Up 28.1% YoY vs H1 FY23 |
| H1 FY24 PAT margin | 25.5%, vs 21.5% in H1 FY23 |
| H1 FY24 gross margin | 56%–57% |
| Employee cost | ~7% of sales, expected to remain in similar range |
| Capacity utilization | ~70% |
| Capacity | A little more than 1,000 KL, adding 50% in next 18 months to reach 1,500 KL |
| H1 FY24 capex | ₹80 cr |
| FY24 capex plan | Another ₹200 cr in next 6 to 9 months |
| FY25 capex plan | Another ₹150 cr, more on greenfield Unit IV |
| Saccharine capacity | 3,500–4,000 metric tons, ~10% of world capacity |